SPG21: A Promising Drug Target for Cancer and Other Diseases (G51324)

Target Name: SPG21

NCBI ID: G51324

SPG21

SPG21: A Promising Drug Target for Cancer and Other Diseases

SPG21 (SPG21019) is a drug target (also known as BM-019) that is being studied for its potential to treat various diseases, including cancer. It is a small protein that is expressed in many different tissues throughout the body, including the brain , heart, and blood vessels.

SPG21 is being investigated for its ability to interfere with the formation of blood-brain barrier (BBB), which is a barrier that separates the brain from the surrounding blood vessels. The BBB is designed to prevent the entry of many different substances into the brain, including drugs that are meant to treat diseases. However, some diseases can bypass the BBB and enter the brain, which can cause serious problems.

SPG21 is thought to be a good candidate for a drug because it is expressed in many different tissues and has been shown to interact with a wide range of proteins. This makes it a good candidate for a drug that can disrupt the BBB and allow drugs to enter the brain.

SPG21 is also being investigated for its potential to treat other diseases, including cancer. Studies have shown that SPG21 can be used to treat various types of cancer, including breast, lung, and ovarian cancer. This is because SPG21 can inhibit the formation of blood -brain barrier, which can allow drugs to reach cancer cells in the brain.

In addition to its potential as a cancer treatment, SPG21 is also being investigated for its potential to treat other diseases. For example, studies have shown that SPG21 can be used to treat inflammation in the brain, including multiple sclerosis. This is because SPG21 can inhibit the formation of blood-brain barrier, which can allow drugs to reach the inflamed cells in the brain.

Overall, SPG21 is a promising drug target that is being studied for its potential to treat a wide range of diseases. Its ability to interact with a wide range of proteins and its potential to treat cancer and other diseases make it a promising candidate for further research .

Protein Name: SPG21 Abhydrolase Domain Containing, Maspardin

Functions: May play a role as a negative regulatory factor in CD4-dependent T-cell activation

The "SPG21 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SPG21 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets